You are here: Industry Insights > Migraine

News List

FDA approves Dr Reddy’s NDA for migraine drug expresspharma
May 07, 2020
The company is working to commercialise Elyxyb (previously known as DFN-15), which is indicated for the acute treatment of migraine with or without aura in adults.
Biohaven Achieves Positive Results in Trial of Migraine Treatment americanpharmaceuticalreview
April 02, 2020
Biohaven Pharmaceutical announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg.
Biohaven to Advance Vazegepant into Phase 3 for Acute Treatment of Migraine americanpharmaceuticalreview
March 26, 2020
Biohaven Pharmaceutical announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant ...
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020
Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.
Biohaven Wins FDA Approval for NURTEC ODT contractpharma
March 18, 2020
Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology.
NICE recommends fremanezumab for chronic migraine prevention europeanpharmaceuticalreview
March 16, 2020
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
Ajovy bags NICE approval pharmatimes
March 13, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Teva’s Ajovy for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.
Biohaven drug wins US FDA approval for use in relieving migraine headaches expresspharma
March 03, 2020
A single oral dose of the 75 mg tablet can provide fast pain relief, return patients to normal function within an hour, and remain effective for up to 48 hours for many patients, the company said.
Allergan scores year-end CGRP nod for migraine med Ubrelvy fiercepharma
December 31, 2019
The CGRP migraine prevention field already has three meds from Amgen, Eli Lilly and Teva vying for market share, and now Allergan has scored the first approval for an oral CGRP to treat migraines as they happen.
Sleep Disturbances May Trigger Migraine drugs
December 27, 2019
Sleep disturbances appear to be a trigger for migraine headaches, according to a new study."We found that low sleep efficiency, which is the amount of time you're awake in bed when ...

Previous page 1 2 3 4 5 6 7 8 9 Next page